- Home
- NRT vs CYCC Comparison
NRT vs CYCC Comparison
Compare NRT & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRT
- CYCC
- Stock Information
- Founded
- NRT 1975
- CYCC 1992
- Country
- NRT United States
- CYCC Malaysia
- Employees
- NRT N/A
- CYCC N/A
- Industry
- NRT Oil & Gas Production
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- NRT Energy
- CYCC Health Care
- Exchange
- NRT Nasdaq
- CYCC Nasdaq
- Market Cap
- NRT 43.1M
- CYCC 61.2M
- IPO Year
- NRT N/A
- CYCC N/A
- Fundamental
- Price
- NRT $5.08
- CYCC $1.63
- Analyst Decision
- NRT
- CYCC
- Analyst Count
- NRT 0
- CYCC 0
- Target Price
- NRT N/A
- CYCC N/A
- AVG Volume (30 Days)
- NRT 42.3K
- CYCC 191.0K
- Earning Date
- NRT 05-30-2025
- CYCC 05-15-2025
- Dividend Yield
- NRT 9.25%
- CYCC 147.24%
- EPS Growth
- NRT N/A
- CYCC N/A
- EPS
- NRT 0.56
- CYCC N/A
- Revenue
- NRT $5,942,748.00
- CYCC $14,000.00
- Revenue This Year
- NRT N/A
- CYCC $137.21
- Revenue Next Year
- NRT N/A
- CYCC N/A
- P/E Ratio
- NRT $9.04
- CYCC N/A
- Revenue Growth
- NRT N/A
- CYCC N/A
- 52 Week Low
- NRT $3.88
- CYCC $1.36
- 52 Week High
- NRT $7.19
- CYCC $49.34
- Technical
- Relative Strength Index (RSI)
- NRT 62.64
- CYCC 32.89
- Support Level
- NRT $4.36
- CYCC $1.36
- Resistance Level
- NRT $5.19
- CYCC $1.94
- Average True Range (ATR)
- NRT 0.23
- CYCC 0.43
- MACD
- NRT 0.03
- CYCC -0.07
- Stochastic Oscillator
- NRT 86.75
- CYCC 8.31
About NRT North European Oil Royality Trust
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.